ClinicalTrials.gg
Enrolling by invitationNCT04633603Updated Dec 12, 2024

LázBarát™ (FeverFriend™) Projekt: Attitude Toward Fever and Its Change in the Healthcare System

An observational study in Fever, Anxiety and Help-Seeking Behavior, sponsored by University of Pecs. Enrolling by invitation at 1 site in Hungary. Open to participants aged Up to 100 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-12-12.

Sponsored by University of Pecs · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
10,000
Ages
Up to 100 Years
Sex
All
01

Study summary

The positive effects of fever are supported by a number of physiological, pathophysiological and clinical evidence. However, the negative attitude toward fever is widespread and have become persistent. According to sociological research, this is based on two main factors: comfort and fear. To change this negative attitude, awareness needs to be raised and the attitude toward fever among health care workers and the lay public needs to be reframed positively. Furthermore, the role of media users is essential, especially among the young generation.

The current Hungarian recommendation/protocol is valid since 2011 (Professional protocol of the Ministry of National Resources: Caring for a child with fever, the recommendation of the College of Pediatric and Pediatric However, the practical implementation among health professionals and the laity public is low.

Based on this protocol and current international guidelines (NICE) clinicians developed a protocol and register, where parents and caregivers can document the symptoms and runoff of fever as well as receive feedback on severity and appropriate management.

The project aims to increase the evidence-based (EBM) guideline adherence, to reduce the unnecessary use of antipyretics and antibiotics, as well as the load on the current healthcare system. The documentation of the collected data allows the investigators to map and analyze (stats) socio-demographic behavior both on individual and societal level.

Read the detailed description

Goal:

Reframing the negative attitude toward fever. Reducing unnecessary use of drugs (antipyretics and antibiotics) as well as lower the number of medical consultations. In order, the investigators will use a media-based mobile application and a web knowledge base. Languages English and Hungarian.

Hypotheses:

  1. The mobile application and knowledge base increases health literacy of parents and professionals.
  2. The application will change the uncertain and/or negative attitude toward fever.
  3. The positive change in attitude will influence antipyretic and consecutive antibiotic use, lower medical provider contact, enhancing the practical implementation of guidelines.

Method:

Noninvasive, noninterventional, self-reported, observational, prospective cohort study under real-life conditions.

Data: provided by caregivers and/or patients are grouped and classified based on the severity of the disease behind the fever.

Data analysis:

Analysis sample size calculation: To analyze guideline-adherent and non-adherent behavior at a 95% binomial confidence interval with an accuracy of +/- 2%, at least 500 fever phases are required if the smaller group comprises 5%. The investigators a-priory estimation based on surveys is that only about 15% of caretakers have a guideline-conforming approach to the management of fever, hence 1,500 fever events are needed for the planned accuracy. If adherent and non-adherent groups are approximately the same size, a maximum of ca. 2,500 fever phases are required.

The exact incidence of fever per age group is not yet known. Larger samples are required - and expected - for subgroup analyses (e.g. between age groups). Recruitment will therefore continue throughout to year 3 and beyond. The Chi² test is used to compare two subgroups. Sample size planning cannot take unplanned multiple testing into account, so the results can only be interpreted exploratively.

Subsample calculations: If a difference of 5% between two frequencies is interpreted as clinically significant, at a power of 80% and an alpha error probability of 5% assuming normal distribution in both subsamples, the following sample sizes are required: For a very rare sample, ca. 200 cases per subsample are sufficient. If the rate is around 50%, ca. 1,600 cases per subsample are required.

Software: IBM SPSS Statistics 22, Microsoft Excel ...

Research partners providing theoretical and professional background:

University of Pécs Hungarian Medical Chamber (Győr-Moson-Sopron Megye) University of Witten Heim Pál Childrens Hospital National Emergency Service Healthware Tanácsadó Kft. Dr. Szőke Henrik és Társa Egészségügyi Szolgáltató Kft.

Organizational tasks are conducted in the framework of the University of Pécs, Faculty of Health Sciences and by the Civil Support Közhasznú Nonprofit Kft.

02

Conditions studied

  • Fever
  • Anxiety
  • Help-Seeking Behavior
  • Virus Diseases
  • Bacterial Infections
  • Overdose of Analgesic Drug

Keywords

  • childhood fever
  • help-seeking behavior
  • fever phobia
  • mobile application
  • guideline adherence
  • antipyretics
  • antibiotics
  • health literacy
  • socio-economic assessment
03

In context

Fever

439 studies on the registry are indexed under Fever; 56 are open to participants now.

This study's planned enrollment of 10,000 is above the median of 408 across 140 observational studies indexed under Fever.

Browse Fever studies →

Lead sponsor

University of Pecs is the lead sponsor of 107 studies on the registry; 25 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 100 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Participants are included if they downloaded and registered the mobile application. The use of the application is voluntary. A minimum of 100 individuals are included, a maximum sample size is not specified. Participants are between the age of 0-100. The target population is mainly children (0-18y).

Eligibility criteria

Inclusion criteria for patients: 0-100 years age, home or ambulant care, accepting the legal notice (including study-protocol, privacy- and data management), documenting patients profile. Eligibility for documentation of separate fever events: recording at least temperature and measurement method (device and place).

Exclusion criteria: severe underlying disease, patient who needs hospitalization.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
10,000 participants (estimated)
Target follow-up
5 Years
Patient registry
Yes

Groups and cohorts

  • All patients

    There is no pre-specified group or subgroup of participant(s) assigned to receive the specific intervention(s) (or no intervention) according to the protocol. All patients get the same possibility to register their data and follow management advice.

    Device: FeverFriend mobile application

Interventions

  • DeviceFeverFriend mobile application

    Registration, documentation of patients profile, documentation of fever events, following advice regarding the patient and the care-giver, documentation of follow up notifications.

    Also known as: FeverFriend web knowledge base (homepage)

06

What researchers measure

Primary outcomes

  1. Fever events outcome, condition of the patient 1

    body temperature grade Celsius

    Time frame: During the period of single fever event (up to 5 days)

  2. Fever events outcome, condition of the patient 2

    duration of fever in days

    Time frame: During the period of single fever event (up to 5 days)

  3. Fever events outcome, condition of the patient 3

    medication, vaccination type and dosage

    Time frame: Before and during the period of single fever event (up to 20 days)

  4. Fever events outcome, condition of the patient 4

    hydration: normal - somewhat decreased - severely decreased

    Time frame: During the period of single fever event (up to 5 days)

  5. Fever events outcome, condition of the patient 5

    ventilation: rate per minute

    Time frame: During the period of single fever event (up to 5 days)

  6. Fever events outcome, condition of the patient 6

    ventilation: wheezing and dyspnea (subjective scale 1-2-3-4-5; minimum 1; maximum 5; 1 is no symptom = better, 5 is the worst)

    Time frame: During the period of single fever event (up to 5 days)

  7. Fever events outcome, condition of the patient 7

    skin condition: color and rash

    Time frame: During the period of single fever event (up to 5 days)

  8. Fever events outcome, condition of the patient 8

    pulse rate beat per minute

    Time frame: During the period of single fever event (up to 5 days)

  9. Fever events outcome, condition of the patient 9

    crying quality (no, normal, abnormal)

    Time frame: During the period of single fever event (up to 5 days)

  10. Fever events outcome, condition of the patient 10

    eating last time in hours

    Time frame: During the period of single fever event (up to 5 days)

  11. Fever events outcome, condition of the patient 11

    urination painful or smelly (yes - no)

    Time frame: During the period of single fever event (up to 5 days)

  12. Fever events outcome, condition of the patient 12

    awareness: normal - sleepy - no (subjective scale; minimum = best = normal; maximum = worst = no)

    Time frame: During the period of single fever event (up to 5 days)

  13. Fever events outcome, condition of the patient 13

    exotic trip in the last 12 month yes - no

    Time frame: During the period of single fever event (up to 5 days)

  14. Fever events outcome, condition of the patient 14

    seizure yes - no

    Time frame: During the period of single fever event (up to 5 days)

  15. Fever events outcome, condition of the patient 15

    wry neck yes - no

    Time frame: During the period of single fever event (up to 5 days)

  16. Fever events outcome, condition of the patient 16

    pain yes - no pain location local - general duration hours

    Time frame: During the period of single fever event (up to 5 days)

  17. Care-givers state 1

    Care-givers own feeling about the progress of patients illness (subjective scale,1 best = optimal - 2 = not sure - 3 = worst = very worried)

    Time frame: During the period of fever event (up to 5 days)

  18. Care-givers state 2

    Care-givers personal opinion about patients state: (subjective scale: minimum = best = not severe, middle = somewhat severe, maximum = worst = very severe)

    Time frame: During the period of fever event (up to 5 days)

  19. Care-givers state 3

    Care-givers self-confidence in handling the situation (subjective scale: maximum = confident; worse = somewhat confident, even worse = not really, minimum = worst = not at all)

    Time frame: During the period of fever event (up to 5 days)

  20. Action taken, evaluation 1

    Use of medication, use of medical providers service, utility of the device and knowledge base

    Time frame: 48 hours after illness resolving

  21. Action taken, evaluation 2

    Use of medication no - yes (type and dosage)

    Time frame: 48 hours after illness resolving

  22. Action taken, evaluation 3

    Use of medical providers service no - yes (institution type)

    Time frame: 48 hours after last fever event documentation

  23. Action taken, evaluation 4

    Utility of the device and knowledge base (subjective scale 1-2-3-4-5; minimum 1 = worst; maximum 5 = best)

    Time frame: 48 hours after last fever event documentation

Other outcomes

  1. Baseline characteristics (profile of patient) 1

    date of birth

    Time frame: at registry on the first day

  2. Baseline characteristics (profile of patient) 2

    gender: male - female - other

    Time frame: at registry on the first day

  3. Baseline characteristics (profile) 3

    height centimeter

    Time frame: at registry on the first day

  4. Baseline characteristics (profile) 4

    weight kilogram

    Time frame: at registry on the first day

  5. Baseline characteristics (profile) 5

    chronic disease yes - no

    Time frame: at registry on the first day

  6. Baseline characteristics (profile) 6

    Former use of medication in the last 12 month (antipyretics, antibiotics) yes - no, number

    Time frame: at registry on the first day

  7. Baseline characteristics (profile) 7

    Former use of healthcare providers service in the last 12 month no - yes, number of events and type of institution

    Time frame: at registry on the first day

  8. Baseline characteristics (profile) 8

    Caregivers former state at fever events of the patient in the last 12 month: care-givers state of mind, level of anxiety, behavior (subjective scale 1-2-3-4; )

    Time frame: at registry on the first day

07

Study locations

1 site
08

References and documents

Publications

  • Purssell E, Collin J. Fever phobia: The impact of time and mortality--a systematic review and meta-analysis. Int J Nurs Stud. 2016 Apr;56:81-9. doi: 10.1016/j.ijnurstu.2015.11.001. Epub 2015 Nov 17. PubMed 26643444 ↗
  • Poirier MP, Collins EP, McGuire E. Fever phobia: a survey of caregivers of children seen in a pediatric emergency department. Clin Pediatr (Phila). 2010 Jun;49(6):530-4. doi: 10.1177/0009922809355312. Epub 2010 May 19. PubMed 20488812 ↗
  • Sakai R, Okumura A, Marui E, Niijima S, Shimizu T. Does fever phobia cross borders? The case of Japan. Pediatr Int. 2012 Feb;54(1):39-44. doi: 10.1111/j.1442-200X.2011.03449.x. Epub 2011 Oct 30. PubMed 21883684 ↗
  • Abu-Baker, N.N., Gharaibeh, H.F., Al-Zoubi, H.M., Savage, C., Gharaibeh, M.K., 2013. Mothers' knowledge and practices of managing minor illnesses of children under five years. J. Res. Nurs. 18 (7), 651-666.
  • Alex-Hart, B.A., Frank-Briggs, A.I., 2011. Mothers' perception of fever management in children. Niger. Health J. 11 (2), 69-72.
  • Ayatollahi, J., Behjati, M., Shahcheraghi, S.H., 2014. Mothers' knowledge, perception and management of fever in children. Paediatr. Today 1 (1), 14-17.
  • Fekete Ferenc dr., Láz, ami átlépi az ingerküszöbünket, Gyermekorvos Továbbképzés, 2014. 13. évf. 1. szám
  • A Nemzeti Erőforrás Minisztérium szakmai protokollja: Lázas gyermekek ellátásáról, Magyar közlöny, 2011
  • Section on Clinical Pharmacology and Therapeutics; Committee on Drugs; Sullivan JE, Farrar HC. Fever and antipyretic use in children. Pediatrics. 2011 Mar;127(3):580-7. doi: 10.1542/peds.2010-3852. Epub 2011 Feb 28. PubMed 21357332 ↗
  • Rawson TM, Moore LS, Tivey AM, Tsao A, Gilchrist M, Charani E, Holmes AH. Behaviour change interventions to influence antimicrobial prescribing: a cross-sectional analysis of reports from UK state-of-the-art scientific conferences. Antimicrob Resist Infect Control. 2017 Jan 13;6:11. doi: 10.1186/s13756-017-0170-7. eCollection 2017. PubMed 28101333 ↗
  • James S, Rao SV, Granger CB. Registry-based randomized clinical trials--a new clinical trial paradigm. Nat Rev Cardiol. 2015 May;12(5):312-6. doi: 10.1038/nrcardio.2015.33. Epub 2015 Mar 17. PubMed 25781411 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2020 (actual). Primary completion is estimated for Jan 2028, 96 months after the start.

Of 51 non-industry observational studies under Fever, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 47. This study's planned 96 months is above that.

Counting every sponsor, half of 61 studies reached it within 22 months; a quarter within 8 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 29, 2020
First posted
Nov 18, 2020
StartActual
Jan 15, 2020
Primary completionEst.
Jan 15, 2028
CompletionEst.
Jan 15, 2028
Last update
Dec 12, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04633603
Lead sponsor
University of Pecs
Collaborators
Dr. Szőke Henrik és Társa Egészségügyi Szolgáltató Kft., Hungarian Medical Chamber / Magyar Orvosi Kamara (Győr-Moson-Sopron Megye), University of Witten, Heim Pál Children's Hospital / Heim Pál Országos Gyermekgyógyászati Intézet, Hungarian Emergency Service / Országos Mentőszolgálat, Civil Support Közhasznú Nonprofit Kft.
Responsible party
Sponsor
First posted
Nov 18, 2020
Start date
Jan 15, 2020
Primary completion
Jan 15, 2028 (estimated)
Completion
Jan 15, 2028 (estimated)
Last update
Dec 12, 2024

Study contacts

Szőke Henrik, Dr
principal investigator · University of Pecs Faculty of Health Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion